Physician

Thomas J Desperito, MD

According to 2025 Medicare claims, Thomas Desperito, MD (NPI: 1265536353) practices urology in the Wilmington, DE-MD-NJ market, with the plurality of this provider's patient population coming from New Castle, DE. This provider's primary affiliated billing organization is BRANDYWINE UROLOGY CONSULTANTS PA (NPI: 1932132248; TIN: 510327125) and primary practice location at 19713-2069. Desperito is affiliated with the eBrightHealth ACO (ACO ID: A3053), participating under the MSSP model.

Desperito's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,612 traditional Medicare patients, billed 16,710 HCPCS/CPT codes, and received $619,081 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,870 prescription claims across 1,117 beneficiaries totaling $2,158,982 in drug costs, led by Xtandi (Enzalutamide). DME data shows 529 claims. Open Payments data shows 48 records totaling $1,428. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $362,315 to $619,081. Similarly, Part D prescription costs have moved sharply higher in recent years, from $254,344 to $2,158,982. In contrast, DME billing represents a smaller volume and rose steadily, from $1,542 to $2,572.